{"schema":"hottub-news/story/v1","story":"st_vl2rair7mrmik6fpqevq","title":"Survodutide induces ‘impressive’ weight loss in type 2 diabetes","title_en":null,"outlets":4,"brief":null,"page":"https://hottub.news/stories/retatrutide-drives-weight-loss-improves-blood-sugar-in-triumph-2-study-vl2rair7mr","count":5,"items":[{"id":"n_pklpxhnrlhtw7wdjavsq","seq":1176951,"kind":"article","title":"Survodutide induces ‘impressive’ weight loss in type 2 diabetes","url":"https://www.healio.com/news/endocrinology/20261001/survodutide-induces-impressive-amount-of-weight-loss-in-type-2-diabetes-and-obesity","summary":"A once-weekly GLP-1/glucagon dual agonist reduced body weight by up to 9.8% at 76 weeks for adults with type 2 diabetes and overweight or obesity, according to findings from the SYNCHRONIZE-2 trial. As Healio previously reported, survodutide (Boehringer Ingelheim/Zealand Pharma), a once-weekly injectable medication, induced weight loss of up to 13% among adults with overweight or obesity without diabetes in the SYNCHRONIZE-1 trial. In new data from the SYNCHRONIZE-2 phase 3…","published":"2026-10-01T14:51:00Z","seen":"2026-10-01T16:38:21Z","lang":"en","source":{"id":"kite-healio-com-23151b","name":"healio.com","domain":"healio.com"},"via":"kite-healio-com-23151b","topics":["medicine"],"authors":["Michael Monostra"],"story":"st_vl2rair7mrmik6fpqevq","category":"health","category_p":0.7200000286102295,"sentiment":"positive","tone":0.5,"political":0.019999999552965164},{"id":"n_itodieln7dtnv4ppuhqa","seq":918253,"kind":"article","title":"Retatrutide confers ‘substantial’ weight loss in type 2 diabetes","url":"https://www.healio.com/news/endocrinology/20260930/retatrutide-confers-substantial-weight-loss-for-adults-with-obesity-type-2-diabetes","summary":"Once-weekly retatrutide induced weight loss of up to 18.8% at 80 weeks for adults with type 2 diabetes plus overweight or obesity, according to findings from the phase 3 TRIUMPH-2 trial. As Healio previously reported, adults with overweight or obesity without diabetes receiving once-weekly subcutaneous retatrutide (Eli Lilly) achieved weight loss of up to 25% at 80 weeks in the TRIUMPH-1 trial. In new data from TRIUMPH-2 presented at the European Association for the Study of…","published":"2026-09-30T12:46:47Z","seen":"2026-09-30T13:50:53Z","lang":"en","source":{"id":"kite-healio-com-23151b","name":"healio.com","domain":"healio.com"},"via":"kite-healio-com-23151b","topics":["medicine"],"authors":["Michael Monostra"],"entities":[{"id":"Q120468350","name":"retatrutide","type":"other"}],"story":"st_vl2rair7mrmik6fpqevq","category":"health","category_p":0.7099999785423279,"sentiment":"positive","tone":0.3799999952316284,"political":0.029999999329447746},{"id":"n_uvqjkzdpblvxnsnazyqq","seq":863045,"kind":"article","title":"TRIUMPH-2: nowe wyniki badania retatrutydu w otyłości i cukrzycy typu 2","title_en":"TRIUMPH-2: new results of the retatrutide study in obesity and type 2 diabetes","url":"https://www.debaty-zdrowie.pl/triumph-2-nowe-wyniki-badania-retatrutydu-w-otylosci-i-cukrzycy-typu-2","summary":"29 września Eli Lilly przedstawiła szczegółowe wyniki badania III fazy TRIUMPH-2 podczas kongresu EASD w Mediolanie. Uczestniczyły w nim osoby z cukrzycą typu 2 oraz otyłością lub nadwagą. Do porównania trzech dawek retatrutydu z placebo przydzielono losowo 1152 uczestników. Leczenie trwało 80 tygodni.","published":"2026-09-30T08:46:40Z","seen":"2026-09-30T09:07:14Z","lang":"pl","source":{"id":"kite-debaty-zdrowie-pl-e257fd","name":"debaty-zdrowie.pl","domain":"debaty-zdrowie.pl"},"via":"kite-debaty-zdrowie-pl-e257fd","topics":["medicine","science / publikacje"],"authors":["Izabela Medolińska"],"story":"st_vl2rair7mrmik6fpqevq","category":"health","category_p":0.7400000095367432,"sentiment":"neutral","tone":0.09000000357627869,"political":0.05999999865889549},{"id":"n_zvn6wvdwuk5y7tnze3qq","seq":805070,"kind":"article","title":"Retatrutide Led to Significant Weight Loss in Newly Published Diabetes Trial","url":"https://www.everydayhealth.com/diabetes/glp-1-drug-retatrutide-led-to-20-percent-weight-loss-in-diabetes-trial","published":"2026-09-30T02:21:31Z","seen":"2026-09-30T02:21:31Z","lang":"en","source":{"id":"everydayhealth.com","name":"everydayhealth.com","domain":"everydayhealth.com","outlet":{"wikidata":"Q5417806","name":"Everyday Health","type":"website","country":"US","designations":["business","news website","public company"]}},"via":"gdelt-gkg-english","topics":["health","economy"],"authors":["Korin Miller"],"entities":[{"id":"Q120468350","name":"retatrutide","type":"other"}],"story":"st_vl2rair7mrmik6fpqevq","category":"health","category_p":0.7300000190734863,"sentiment":"positive","tone":0.17000000178813934,"political":0.019999999552965164},{"id":"n_vl2rair7mrmik6fpqevq","seq":780708,"kind":"article","title":"Retatrutide Drives Weight Loss, Improves Blood Sugar in TRIUMPH-2 Study","url":"https://www.miragenews.com/retatrutide-drives-weight-loss-improves-blood-1752164","published":"2026-09-29T22:40:41Z","seen":"2026-09-29T22:40:41Z","lang":"en","source":{"id":"miragenews.com","name":"miragenews.com","domain":"miragenews.com"},"via":"gdelt-gkg-english","topics":["economy","health"],"entities":[{"id":"Q120468350","name":"retatrutide","type":"other"}],"story":"st_vl2rair7mrmik6fpqevq","category":"health","category_p":0.7699999809265137,"sentiment":"positive","tone":-0.15000000596046448,"political":0.019999999552965164}]}